靶向治疗是非小细胞肺癌(non-small cell lung cancer,NSCLC)患者肿瘤切除术后进行的一项标准化治疗策略,旨在改善患者的生活状况,减少肿瘤复发的风险。其中应用最多的药物靶点就是表皮生长因子受体(epidermal growth factor receptor,EGFR)。然而,在现阶段的用药环境中,由于药物对于EGFR基因自身的影响,部分患者的基因会产生继发性的突变,不可避免地对治疗药物程度不一的耐受,在接受其他类型治疗的患者中也发现了相应的此类突变。在肿瘤细胞内高度的异质性与适应性作用下,EGFR基因的继发性突变会引起细胞信号通路的改变,继而影响肿瘤细胞的生长和转移。在面对EGFR继发突变的NSCLC患者时往往需要因地制宜地采取个性化的治疗方案以延缓病情发展。本文作者就EGFR基因在不同的治疗环境下发生的继发突变类型、预后以及相关治疗的研究进展进行综述。

[1] BENJAMIN D J,HASLAM A,GILL J,et al.Targeted therapy in lung cancer:are we closing the gap in years of life lost?[J].Cancer Med,2022,11(18):3417-3424.
[2] 中华医学会呼吸病学分会肺癌学组,中国呼吸肿瘤协作组.呼吸道传染病——新型冠状病毒肺炎流行期间晚期非小细胞肺癌患者诊疗专家指引(试行)[J].中华结核和呼吸杂志,2020,43(4):297-301.
[3] SHI J F,WANG L,WU N,et al.Clinical characteristics and medical service utilization of lung cancer in China,2005-2014:overall design and results from a multicenter retrospective epidemiologic survey[J].Lung Cancer,2019,128:91-100.
[4] 金美华,唐娟,秦家丽,等.2002-2020年间的肺癌流行病学分析[J].华夏医学,2021,34(6):34-38.
[5] NAGASAKA M,GADGEEL S M.Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer[J].Expert Rev Anticancer Ther,2018,18(1):63-70.
[6] SABBAH D A,HAJJO R,SWEIDAN K.Review on epidermal growth factor receptor(EGFR) structure,signaling pathways,interactions,and recent updates of EGFR inhibitors[J].Curr Top Med Chem,2020,20(10):815-834.
[7] WU Y L,JOHN T,GROHE C,et al.Postoperative chemotherapy use and outcomes from ADAURA:osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC[J].Thorac Oncol,2022,17(3):423-433.
[8] ZHAI H,ZHONG W,YANG X,et al.Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) therapy for lung cancer[J].Transl Lung Cancer Res,2015,4(1):82-93.
[9] MARUSHIMA H,KIMURA H,MIYAZAWA T,et al.Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer:FAST-nab[J].Anticancer Drugs,2020,31(2):177-182.
[10] PIGNON J P,TRIBODET H,SCAGLIOTTI G V,et al.Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group[J].J Clin Oncol,2008,26(21):3552-3559.
[11] CHIN T M,QUINLAN M P,SINGH A,et al.Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure:a cell culture model of second-line erlotinib treatment[J].Clin Cancer Res,2008,14(21):6867-6876.
[12] WANG S,AN T,DUAN J,et al.Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer[J].PLoS One,2013,8(3):e51021.
[13] WANG H,YANG X,SUN Y,et al.Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer[J].Transl Cancer Res,2020,9(1):372-381.
[14] WANG Z,ZHANG L,XU W,et al.The multi-omics analysis of key genes regulating EGFR-TKI resistance,immune infiltration,SCLC transformation in EGFR-mutant NSCLC[J].J Inflamm Res,2022,15:649-667.
[15] QI W X,SHEN Z,LIN F,et al.Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer:a systematic review and meta-analysis[J].Asian Pac J Cancer Prev,2012,13(10):5177-5182.
[16] REMON J,STEUER C E,RAMALINGAM S S,et al.Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients[J].Ann Oncol,2018,29(suppl_1):i20-i27.
[17] HE J,HUANG Z,HAN L,et al.Mechanisms and management of 3rd generation EGFRTKI resistance in advanced nonsmall cell lung cancer(Review)[J].Int J Oncol,2021,59(5):90.
[18] REGUART N,REMON J.Common EGFR-mutated subgroups(Del19/L858R) in advanced non-small-cell lung cancer:chasing better outcomes with tyrosine-kinase inhibitors[J].Future Oncol,2015,11(8):1245-1257.
[19] PAPADIMITRAKOPOULOU V A,WU Y L,HAN J Y,et al.LBA51 analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study[J/OL].Ann Oncol,https://doi.org/10.1093/annonc/mdy424.064(2018).
[20] WANG Q,YANG S,WANG K,et al.MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer[J].J Hematol Oncol,2019,12(1):63.
[21] LU S,WANG Q,ZHANG G,et al.Efficacy of aumolertinib(HS-10296) in patients with advanced EGFR T790M+ NSCLC:updated post-national medical products administration approval results from the APOLLO registrational trial[J].J Thorac Oncol,2022,17(3):411-422.
[22] GUO R,LUO J,CHANG J,et al.MET-dependent solid tumours-molecular diagnosis and targeted therapy[J].Nat Rev Clin Oncol,2020,17(9):569-587.
[23] OXNARD G R,ARCILA M E,SIMA C S,et al.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer:distinct natural history of patients with tumors harboring the T790M mutation[J].Clin Cancer Res,2011,17(6):1616-1622.
[24] ENGELMAN J A,ZEJNULLAHU K,MITSUDOMI T,et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J].Science,2007,316(5827):1039-1043.
[25] BEAN J,BRENNAN C,SHIH J Y,et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J].Proc Natl Acad Sci USA,2007,104(52):20932-20937.
[26] YANO S,WANG W,LI Q,et al.Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations[J].Cancer Res,2008,68(22):9479-9487.
[27] SEQUIST L V,HAN J Y,AHN M J,et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive,MET-amplified,non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors:interim results from a multicentre,open-label,phase 1b study[J].Lancet Oncol,2020,21(3):373-386.
[28] YU H A,ARCILA M E,REKHTMAN N,et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J].Clin Cancer Res,2013,19(8):2240-2247.
[29] KO B,PAUCAR D,HALMOS B.EGFR T790M:revealing the secrets of a gatekeeper[J].Lung Cancer(Auckl),2017,8:147-159.
[30] WANG Y,LI L,HAN R,et al.Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib[J].Lung Cancer,2018,118:105-110.
[31] OXNARD G R,ARCILA M E,SIMA C S,et al.Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer:distinct natural history of patients with tumors harboring the T790M mutation[J].Clin Cancer Res,2011,17(6):1616-1622.
[32] MOK T S,WU Y L,AHN M J,et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J].N Engl J Med,2017,376(7):629-640.
[33] SHI Y,HU X,ZHANG S,et al.Efficacy,safety,and genetic analysis of furmonertinib(AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer:a phase 2b,multicentre,single-arm,open-label study[J].Lancet Respir Med,2021,9(8):829-839.
[34] LU S,WANG Q,ZHANG G,et al.Final results of APOLLO study:overall survival(OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer(NSCLC)[J].Ann Oncol,2021,32:S949-S1039.
[35] NISHINO M,SUDA K,KOBAYASHI Y,et al.Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro[J].Lung Cancer,2018,126:149-155.
[36] WU Y L,TSUBOI M,HE J,et al.Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J].N Engl J Med,2020,383(18):1711-1723.
[37] PIPER-VALLILLO A J,SEQUIST L V,PIOTROWSKA Z.Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib:a review[J/OL].J Clin Oncol,2020.doi:10.1200/JCO.19.03123.
[38] CHABON J J,SIMMONS A D,LOVEJOY A F,et al.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J].Nat Commun,2016,7:11815.
[39] LIN C C,SHIH J Y,YU C J,et al.Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib:a genomic study[J].Lancet Respir Med,2018,6(2):107-116.
[40] FANG G,LIU W,SHANG Y,et al.Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI:a case report[J].Ann Transl Med,2022,10(2):115.
[41] TANG H,SHRAGER J B.CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer:a personalized molecular surgical therapy[J].EMBO Mol Med,2016,8(2):83-85.
[42] ILIE M,HOFMAN V,DIETEL M,et al.Assessment of the PD-L1 status by immunohistochemistry:challenges and perspectives for therapeutic strategies in lung cancer patients[J].Virchows Arch,2016,468(5):511-525.
[43] AKBAY E A,KOYAMA S,CARRETERO J,et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors[J].Cancer Discov,2013,3(12):1355-1363.
[44] JIA Y,LI X,JIANG T,et al.EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors:implications for combination therapies[J].Int J Cancer,2019,145(5):1432-1444.
[45] OXNARD G R,YANG J C,YU H,et al.TATTON:a multi-arm,phase Ib trial of osimertinib combined with selumetinib,savolitinib,or durvalumab in EGFR-mutant lung cancer[J].Ann Oncol,2020,31(4):507-516.
[46] YANG J C,SHEPHERD F A,KIM D W,et al.Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy:CAURAL brief report[J].J Thorac Oncol,2019,14(5):933-939.
[47] QIAO M,JIANG T,LIU X,et al.Immune checkpoint inhibitors in EGFR-mutated NSCLC:dusk or dawn?[J].J Thorac Oncol,2021,16(8):1267-1288.
[48] OUYANG W,O'GARRA A.IL-10 family cytokines IL-10 and IL-22:from basic science to clinical translation[J].Immunity,2019,50:871-891.